A Randomized Controlled Trial of Growth Hormone in Active Pediatric Crohn Disease

Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, Cincinnati Children's Hospital Medical Center and the University of Cincinnati College of Medicine, Cincinnati, OH, USA.
Journal of pediatric gastroenterology and nutrition (Impact Factor: 2.63). 05/2010; 51(2):130-9. DOI: 10.1097/MPG.0b013e3181c992d6
Source: PubMed


Growth hormone (GH) may reduce symptoms and improve growth in Crohn disease (CD). The effect on mucosal inflammation is not known. We hypothesized that GH would improve both clinical and mucosal disease activity and stimulate linear growth in pediatric CD.
Twenty patients ages 7 to 18 receiving corticosteroids (CTX) for active CD were randomized to begin GH, 0.075 mg x kg(-1) x day(-1) (group A), or continue CTX alone (group B). Clinical and endoscopic disease activities were assessed after 12 weeks. Group B began GH at 12 weeks, and clinical disease activity was assessed at 24 weeks. Subjects who experienced a clinical response after 12 weeks of GH therapy continued treatment for an additional 52 weeks, and linear growth was assessed.
Sixty-five percent of patients receiving GH achieved clinical remission, compared with 20% treated with CTX alone (P = 0.03). Although endoscopic disease activity trended toward an improvement at week 12 in group A, this did not differ between the groups. Sixty-one percent of week 12 GH responders maintained their clinical response through week 64. Mean (95th confidence interval) height z score on GH increased from -1.1 (-1.6, -0.6) to -0.4 (-1, 0.2), P = 0.004 during this 52-week extension phase. GH was well tolerated with no unexpected safety signals.
The addition of GH to CTX therapy did not induce a reduction in mucosal inflammation, relative to CTX alone. However, GH was safe and effective as an adjunct to CTX for treatment of clinical disease activity and growth failure in pediatric CD.

Download full-text


Available from: Cade M Nylund,
  • Source
    • "Recombinant human growth hormone (hGH) is used to treat growth disorders and metabolic dysfunctions, related or unrelated to growth hormone deficiency. For instance, hGH is used as treatment in children with chronic kidney disease [12], in patients with Crohn's disease [13], Turner syndrome or Noonan syndrome [14]. GHR is also the target of GH antagonist in acromegaly treatment. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Growth hormone is at the focus of many pharmacological interests, due to its implication in the regulation of key biological processes. Its characteristic ligand-receptor interaction scheme, in an asymmetric and sequential 1:2 configuration, induces important self-regulatory properties that determine the dynamics and strength of the signaling. Here we use a mathematical approach to unveil the consequences of the differential binding process and its relevance in the regulation of the assembly of the active complex. Several mathematical models are developed to an- alyze the role of each of the two different affinity binding sites of the ligand towards each of the receptors in the complex. The models allow us to study the emergence of key properties of the system due to the dif- ferential and sequential binding, such as adaptation, self-antagonism at high ligand concentrations and homodimer enhanced activation. These theoretical and computational approaches help us to optimize the design of agonist and antagonist molecules to develop more efficient treatments against growth hormone related diseases.
    Growth Hormones: Synthesis, Regulation and Health Implications, 1st edited by Anne Andersdtr, Jon Anderssen, 05/2012: chapter 2; Nova Publisher., ISBN: 978-1-61942-681-8
  • Source
    • "None of the reports of ghrelin administration in colitis have included levels of growth hormone or IGF-1, though studies of GHS-1a agonist treatment in cachexia have reported increased levels of IGF-1 [70]. Use of growth hormone as a treatment for IBD has resulted in increased linear growth [46] but not an improvement in disease activity [71], suggesting that this is not a primary mechanism by which ghrelin improves colitis. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Inflammatory bowel diseases (IBD)-and in particular Crohn's disease-are immune-mediated processes that result in denuded intestinal mucosa and can produce decreased appetite, weight loss, and systemic inflammation. Current treatments include anti-inflammatory medications, immunomodulators, and feeding interventions. Ghrelin is an endogenous orexigenic hormone that directly stimulates growth hormone release, increases gut motility, and has cardiovascular and anti-inflammatory properties. Although ghrelin levels are elevated in active IBD, administration of ghrelin in most (but not all) animal models of colitis has produced improvements in disease activity and systemic inflammation. The mechanism for these effects is not known but may relate to decreased inflammation, increased motility, increased appetite, and increased colonic blood flow. Human trials have not been performed, however, and more research is clearly needed.
    International Journal of Peptides 08/2011; 2011(1687-9767):189242. DOI:10.1155/2011/189242
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: It is unclear whether recombinant human growth hormone (rhGH) improves linear growth in children with Crohn's disease (CD). To investigate the effects of rhGH on height velocity (HV) and glucose homeostasis over a 6-month period. Randomized controlled trial in two tertiary children's hospitals in 22 children with inflammatory bowel disease amongst whom 21 had CD. Duration of disease from diagnosis and number of acute relapses requiring either exclusive enteral nutrition or therapeutic dose of oral prednisolone were similar in the treatment and control groups. Either rhGH (0·067 mg/kg per day) as daily subcutaneous injections (rhGH group; n, 11) or no rhGH, (Ctrl; n, 11) for 6 months. Percentage change in HV after 6 months in the two groups. Auxology, puberty, skeletal age, disease factors, treatment and glucose homeostasis were also assessed. Median HV increased from 4·5 (range, 0·6, 8·9) at baseline to 10·8 (6·1, 15·0) cm/year at 6 month (P = 0·003) in the rhGH group, whereas in the Ctrl group, it was 3·8 (1·4, 6·7) and 3·5 cm/year (2·0, 9·6), respectively (P = 0·58). Median percentage increase in HV after 6 months in the rhGH group was 140% (16·7, 916·7) compared with 17·4% (-42·1%, 97·7%) in the Ctrl group (P < 0·001). There were no significant differences in disease activity and proinflammatory cytokines at baseline and 6 months in both groups and change in bone age for chronological age was also similar in the two groups. In the rhGH group, fasting insulin increased from 4·0 (2·0, 11·0) to 7·0 mU/l (2·0, 16·0) (P = 0·02), whereas in the Ctrl group, it was 3·0 (1·2, 12·7) and 3·8 mU/l (2·1, 7·0) (P = 0·72), respectively. Although this pilot trial shows that rhGH can improve short-term linear growth in children with CD, the clinical efficacy of this therapy needs to be further studied in longer-term studies of growth, glucose homeostasis and disease status.
    Clinical Endocrinology 05/2011; 74(5):599-607. DOI:10.1111/j.1365-2265.2011.03977.x · 3.46 Impact Factor
Show more